These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29021896)

  • 1. Disease modification and Neuroprotection in neurodegenerative disorders.
    Cummings J
    Transl Neurodegener; 2017; 6():25. PubMed ID: 29021896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining Disease Modifying Therapy for Alzheimer's Disease.
    Cummings J; Fox N
    J Prev Alzheimers Dis; 2017; 4(2):109-115. PubMed ID: 29071250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of basket trials in drug development for neurodegenerative disorders.
    Cummings J; Montes A; Kamboj S; Cacho JF
    Alzheimers Res Ther; 2022 May; 14(1):73. PubMed ID: 35614479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force.
    Cummings J; Fox N; Vellas B; Aisen P; Shan G
    J Prev Alzheimers Dis; 2018; 5(2):103-109. PubMed ID: 29616703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.
    Cummings J; Ritter A; Zhong K
    J Alzheimers Dis; 2018; 64(s1):S3-S22. PubMed ID: 29562511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders.
    Vissers MFJM; Heuberger JAAC; Groeneveld GJ
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusion tensor magnetic resonance imaging for single subject diagnosis in neurodegenerative diseases.
    Sajjadi SA; Acosta-Cabronero J; Patterson K; Diaz-de-Grenu LZ; Williams GB; Nestor PJ
    Brain; 2013 Jul; 136(Pt 7):2253-61. PubMed ID: 23729473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining and labeling disease-modifying treatments for Alzheimer's disease.
    Cummings JL
    Alzheimers Dement; 2009 Sep; 5(5):406-18. PubMed ID: 19751920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychopharmacological neuroprotection in neurodegenerative diseases, part III: criteria-based assessment: a report of the ANPA committee on research.
    Lauterbach EC; Mendez MF
    J Neuropsychiatry Clin Neurosci; 2011; 23(3):242-60. PubMed ID: 21948886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances of Zebrafish in Neurodegenerative Disease: From Models to Drug Discovery.
    Wang X; Zhang JB; He KJ; Wang F; Liu CF
    Front Pharmacol; 2021; 12():713963. PubMed ID: 34335276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health System Change for Alzheimer's Disease-Modifying Therapies in Canada: Beginning the Discussion.
    Frank A; Ismail Z; Wilson M; Gauthier S; Verret L; Hsiung GR; Borrie M
    Can J Neurol Sci; 2023 Dec; ():1-9. PubMed ID: 38052729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials.
    Cummings JL
    Alzheimers Dement; 2006 Oct; 2(4):263-71. PubMed ID: 19595897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing ionic mechanisms to achieve disease modification in neurodegenerative disorders.
    Masi A; Narducci R; Mannaioni G
    Pharmacol Res; 2019 Sep; 147():104343. PubMed ID: 31279830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Links between frontotemporal lobar degeneration, corticobasal degeneration, progressive supranuclear palsy, and amyotrophic lateral sclerosis.
    Boeve BF
    Alzheimer Dis Assoc Disord; 2007; 21(4):S31-8. PubMed ID: 18090421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic advances in multiple system atrophy and progressive supranuclear palsy.
    Poewe W; Mahlknecht P; Krismer F
    Mov Disord; 2015 Sep; 30(11):1528-38. PubMed ID: 26227071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates of cerebral atrophy differ in different degenerative pathologies.
    Whitwell JL; Jack CR; Parisi JE; Knopman DS; Boeve BF; Petersen RC; Ferman TJ; Dickson DW; Josephs KA
    Brain; 2007 Apr; 130(Pt 4):1148-58. PubMed ID: 17347250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and biological phenotypes of frontotemporal dementia: Perspectives for disease modifying therapies.
    Gazzina S; Manes MA; Padovani A; Borroni B
    Eur J Pharmacol; 2017 Dec; 817():76-85. PubMed ID: 28579383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroimaging in neurodegenerative dementias.
    McGinnis SM
    Semin Neurol; 2012 Sep; 32(4):347-60. PubMed ID: 23361481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free and Cued Selective Reminding Test - accuracy for the differential diagnosis of Alzheimer's and neurodegenerative diseases: A large-scale biomarker-characterized monocenter cohort study (ClinAD).
    Teichmann M; Epelbaum S; Samri D; Levy Nogueira M; Michon A; Hampel H; Lamari F; Dubois B
    Alzheimers Dement; 2017 Aug; 13(8):913-923. PubMed ID: 28222300
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.